Safety and efficacy evaluation of low-dose trimethoprim-sulfamethoxazole for prophylaxis of Pneumocystis pneumonia in HIV uninfected patients undergoing hemodialysis: a retrospective observational study

Table 2 Factor for TMP-SMX discontinuation rate

Factor	HR	95% CI	P-value
Low-dose group (vs standard-dose)	0.18	0.04–0.86	0.032
Age (over 60 years)	2.54	0.56–11.5	0.230
Sex (men vs female)	1.61	0.56–4.7	0.380
Disease
Hematological malignancy (reference)	1.00	–	–
Autoimmune disease	1.37	0.29–6.4	0.690
Other disease	0.26	0.02–3.4	0.310
Treatment
Low PSL dose	1.00
High PSL dose	0.30	0.05–1.9	0.200
Others	0	0–0	< 0.001

The risk factors for TMP-SMX discontinuation using the Cox Fine and Gray method were described as adjusted hazard ratios and 95% CIs. The adjusted covariates were selected clinically and included the following: age, sex, dosage of TMP-SMX, and underlying disease
Abbreviations: TMP-SMX trimethoprim-sulfamethoxazole, HR hazard ratio, CI confidence interval, PSL Prednisolone

ISSN: 1471-2334